Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N03AF04
|
| gptkbp:CASNumber |
236395-14-5
|
| gptkbp:chemicalFormula |
C15H15N2NaO2
|
| gptkbp:drugClass |
anticonvulsant
|
| gptkbp:eliminationHalfLife |
13-20 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericName |
gptkb:eslicarbazepine_acetate
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aptiom
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sunovion_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
voltage-gated sodium channel blocker
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting dizziness fatigue headache drowsiness double vision |
| gptkbp:usedFor |
epilepsy
partial-onset seizures |
| gptkbp:bfsParent |
gptkb:Sumitomo_Pharma
gptkb:Sumitomo_Dainippon_Pharma |
| gptkbp:bfsLayer |
6
|